Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nathan Turner

Physician Assistant Annapolis, MD Physician Assistant

NPI 1508242595 CMS profile 10563926

116 Defense Hwy, Suite 403, Annapolis, MD 21401

Open in the dashboard

General payments

$11,028

460 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Turner of Annapolis, MD is reported in the CMS Open Payments database as having received $11,028 across 460 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,843 101
2024 General $1,862 100
2023 General $1,725 80
2022 General $3,120 78
2021 General $1,477 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Turner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nathan Turner were reported at $2,843. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nathan Turner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,477 $132 $37–$438 $132
2022 $3,120 $155 $48–$522 $149
2023 $1,725 $167 $52–$557 $160
2024 $1,862 $178 $55–$600 $164
2025 $2,843 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $4,259 106 payments
  2. AbbVie, Inc. $1,727 100 payments
  3. Collegium Pharmaceutical, Inc. $1,176 69 payments
  4. Medtronic, Inc. $1,055 21 payments
  5. Pfizer Inc. $489 25 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $377 36 payments
  7. Nevro Corp. $244 10 payments
  8. Biohaven Pharmaceuticals, Inc. $210 12 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $196 13 payments
  10. Horizon Therapeutics plc $153 15 payments
  11. Other $1,141 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,111 449 payments
  2. Travel and Lodging $1,875 9 payments
  3. Education $42 2 payments
Products named General payments · program years 2021–2025
  1. Spectra WaveWriter $2,077 13 payments
  2. WaveWriter Alpha Prime 16 $1,784 81 payments
  3. UBRELVY $1,298 76 payments
  4. SYNCHROMEDII $921 16 payments
  5. QULIPTA $768 53 payments
  6. XTAMPZA $694 43 payments
  7. BELBUCA $482 26 payments
  8. NURTEC ODT Pain $470 24 payments
  9. NURTEC ODT Primary Care $406 25 payments
  10. RELISTOR $377 36 payments
  11. Other $3,403 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

5,079

Median for Physician Assistant: 241

Drug cost

$424,594

Median for Physician Assistant: $4,110

Branded share of claims

31.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 47 $66,600
Belbuca Buprenorphine Hcl Brand 64 $55,431
Relistor Methylnaltrexone Bromide Brand 22 $49,724
Oxycontin Oxycodone Hcl Brand 58 $42,880
Diclofenac Sodium Generic 202 $27,380
Xtampza Er Oxycodone Myristate Brand 44 $25,080
Lidocaine Generic 168 $21,999
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 522 $20,924
Ztlido Lidocaine Brand 26 $18,725
Oxycodone Hcl Generic 951 $17,675

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$277,412

Of which drugs: $5,336

Medicare patients

344

Average age 68

Services billed

6,533

201 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Depression 41%
COPD 29%
Ischemic heart disease 25%
Chronic kidney disease 25%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 13 720 $74

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $277
$277 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $220
$220 64 —
QULIPTA
  • AbbVie, Inc. $159
$159 — —
NURTEC ODT
  • PFIZER INC. $140
$140 47 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $78
$78 44 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record